Our FHCRC/UW CFAR proposal focuses on three major themes: preventing HIV-1 infection, eradication and co-morbidities. Basic research in each of these areas will require sophisticated immunologic assessments, for example, target cell identification/quantification (HIV prevention), vaccine-induced immune responses (HIV prevention), immune activation status (pathogenesis) and latent cell identification/quantification (eradication). The Immunology Core will offer to all CFAR investigators innovative new and cutting-edge technologies (e.g., CyTOF, digital drop PCR and Cyntellect LEAP for single cell analyses) to assess molecular and cellular immune phenotypes and functions in diverse tissue types. The Core will dedicate its primary effort on training new/early investigators to apply these technologies to address fundamental research in the three areas. In addition, the core proposes to expand its scope to mucosal immunology, non-human primate immunology and the immunology of co-infections, and Seattle experts in these areas will join our core. The focus on new technologies and the addition of new experts place the Immunology Core in a very strong position to facilitate basic research in the new focus areas. In addition, the Core will continue to provide access to the humoral and cellular assays and expertise that currently comprise our Core.
The overarching goal of the Immunology Core is to facilitate cutting-edge immunologic assessments of diverse biologic specimen types to answer basic science questions related to HIV prevention, eradication and co-morbidities.
|Stekler, Joanne D; McKernan, Jennifer; Milne, Ross et al. (2015) Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013. Antivir Ther 20:77-80|
|Mohanraj, Rani; Jeyaseelan, Visalakshi; Kumar, Shuba et al. (2015) Cultural adaptation of the Brief COPE for persons living with HIV/AIDS in southern India. AIDS Behav 19:341-51|
|Slyker, Jennifer A; Casper, Corey; Tapia, Kenneth et al. (2014) Accelerated suppression of primary Epstein-Barr virus infection in HIV-infected infants initiating lopinavir/ritonavir-based versus nevirapine-based combination antiretroviral therapy. Clin Infect Dis 58:1333-7|
|Mackelprang, Romel D; Bigham, Abigail W; Celum, Connie et al. (2014) Toll-like receptor polymorphism associations with HIV-1 outcomes among sub-Saharan Africans. J Infect Dis 209:1623-7|
|Gantt, Soren; Cattamanchi, Ashok; Krantz, Elizabeth et al. (2014) Reduced human herpesvirus-8 oropharyngeal shedding associated with protease inhibitor-based antiretroviral therapy. J Clin Virol 60:127-32|
|Puttkammer, Nancy H; Zeliadt, Steven B; Balan, Jean Gabriel et al. (2014) Before and after the earthquake: a case study of attrition from the HIV antiretroviral therapy program in Haiti. Glob Health Action 7:24572|
|Gerdts, Sarah E; Wagenaar, Bradley H; Micek, Mark A et al. (2014) Linkage to HIV care and antiretroviral therapy by HIV testing service type in Central Mozambique: a retrospective cohort study. J Acquir Immune Defic Syndr 66:e37-44|
|Liu, Yi; Rao, Ushnal; McClure, Jan et al. (2014) Impact of mutations in highly conserved amino acids of the HIV-1 Gag-p24 and Env-gp120 proteins on viral replication in different genetic backgrounds. PLoS One 9:e94240|
|Chung, Michael H; Beck, Ingrid A; Dross, Sandra et al. (2014) Oligonucleotide ligation assay detects HIV drug resistance associated with virologic failure among antiretroviral-naive adults in Kenya. J Acquir Immune Defic Syndr 67:246-53|
|Pantalone, David W; Huh, David; Nelson, Kimberly M et al. (2014) Prospective predictors of unprotected anal intercourse among HIV-seropositive men who have sex with men initiating antiretroviral therapy. AIDS Behav 18:78-87|
Showing the most recent 10 out of 552 publications